MNPR
Monopar Therapeutics Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
Monopar Therapeutics (MNPR) Stock: Buy, Sell, or Hold?
$71.73
-0.05 (-0.07%)
âŧ
5d:
-1.48%
30d:
-0.49%
90d:
-35.03%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (87%)
Quality Score
47/100
Position
FAIR
30-Day Fair Range
$69.09 â $77.49
Position: FAIR
Forward P/E & Valuation
-37.4x
Next 12M consensus est.
Wall Street Target
$129.92
+81.1% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$64.95 / $82.51
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: MNPR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
Get Alerted When MNPR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: MNPR is currently trading at $71.73, which is considered fair relative to its 30-day fair value range of $69.09 to $77.49.
Technical Outlook: Technically, MNPR is in a strong downtrend. Immediate support is located at $64.95, while resistance sits at $82.50.
Market Sentiment: MNPR scores 71/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $129.92 (+81.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MNPR is in a strong downtrend. Immediate support is located at $64.95, while resistance sits at $82.50.
Market Sentiment: MNPR scores 71/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $129.92 (+81.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$69.09 -
$77.49
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.8%
Trading Range & Key Levels
30-Day Trading Range
$69.09 -
$77.49
Current vs Trading Range
FAIR
Support Level
$64.95
Resistance Level
$82.51
Current Trend
Strong Downtrend
Technical data as of
Nov 11, 2026
Quantitative Signal Breakdown
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (71/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 81.1% below Wall St target ($129.92)
- WARNING: Composite score 47/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-37.44
Wall Street Target
$129.92
(+81.1%)
Share MNPR Analysis
Share this live MNPR analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (MNPR)
Bullish
1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Jul 22, 2026
Daily AI digest
AI Retail Discussion Summary:
Monopar Therapeutics announced the initiation of a rolling NDA submission for ALXN1840 in Wilson Disease, marking an important milestone towards potential FDA approval.
Key Retail Themes:
FDA NDA submission
Potential approval of ALXN1840
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 2:43 AM ET
Data refreshes hourly during market hours. Next update: 3:43 AM
Data refreshes hourly during market hours. Next update: 3:43 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MNPR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$145 | 31 SELL |
|
ARGX
argenx NV ADR |
STRONG BUY
23 analysts |
$1147 | 35 SELL |
|
BNTX
BioNTech SE |
BUY
21 analysts |
$114 | 62 BUY |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 41 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 39 SELL |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive MNPR Research Pages
